title: Effects of isoflurane on electrophysiological measurements in children with the Wolff-Parkinson-White syndrome.
abstract: This study was designed to assess the effects of isoflurane (ISO) on the electrophysiological properties of the accessory pathway, atrium, ventricle, and AV node in children with the Wolff-Parkinson-White (WPW) syndrome. The results of programmed electrical stimulation were analyzed in 51 patients (4 months to 17 years of age) with WPW. The study population was divided into two groups. Twenty-seven patients received local anesthesia and intramuscular injection of meperidine, promethazine, and chlorpromazine (MPC group). Twenty-four patients received general anesthesia with ISO inhalation (ISO group). We compared the antegrade effective refractory period of the accessory pathway (antegrade APERP), ventricular effective refractory period (VERP), atrial effective refractory period (AERP), AH interval, and cycle length of circus movement tachycardia (CMT-CL) in 12 pairs of age and sex matched patients selected from the MPC and ISO groups. Of the 12 pairs of age and sex matched patients, antegrade APERP in patients who received ISO (299 +/- 17 ms, mean +/- SEM) was significantly longer as compared with matched patients in the MPC group (262 +/- 5 ms, P < 0.025). The VERP and AERP in patients from the ISO group were significantly prolonged compared with the MPC patients (239 +/- 7 vs 210 +/- 8 ms, P < 0.025, and 228 +/- 11 vs 180 +/- 6 ms, P < 0.01, respectively). There was no significant difference in the AH interval or CMT-CL between the two subgroups. Thus, ISO prolongs the antegrade APERPs as well as the effective refractory periods of atrial and ventricular muscle in children with WPW, while the AH interval and CMT-CL appear to be unaffected. Care must be taken in interpreting measurements of the antegrade APERP made in patients under general anesthesia for RF ablation of accessory pathways.
authors.affiliation: Department of Pediatrics, UCLA School of Medicine 90095, USA.
authors.forename: R K
authors.initials: RK
authors.lastname: Chang
authors.forename: W G
authors.initials: WG
authors.lastname: Stevenson
authors.forename: G T
authors.initials: GT
authors.lastname: Wetzel
authors.forename: K
authors.initials: K
authors.lastname: Shannon
authors.forename: V C
authors.initials: VC
authors.lastname: Baum
authors.forename: T S
authors.initials: TS
authors.lastname: Klitzner
mesh_terms: D000759:Adjuvants, Anesthesia / Q000494:pharmacology; D000769:Anesthesia, Inhalation; D000772:Anesthesia, Local; D018685:Anesthetics, Inhalation / Q000494:pharmacology*; D002304:Cardiac Pacing, Artificial; D016022:Case-Control Studies; D017115:Catheter Ablation; D002648:Child; D002746:Chlorpromazine / Q000494:pharmacology; D005260:Female; D006329:Heart Conduction System / Q000187:drug effects* / Q000503:physiopathology; D006801:Humans; D006993:Hypnotics and Sedatives / Q000494:pharmacology; D007530:Isoflurane / Q000494:pharmacology*; D008297:Male; D008614:Meperidine / Q000494:pharmacology; D011398:Promethazine / Q000494:pharmacology; D012189:Retrospective Studies; D014927:Wolff-Parkinson-White Syndrome / Q000175:diagnosis / Q000503:physiopathology* / Q000601:surgery
chemical_list: D000759:Adjuvants, Anesthesia; D018685:Anesthetics, Inhalation; D006993:Hypnotics and Sedatives; D008614:Meperidine; D007530:Isoflurane; D011398:Promethazine; D002746:Chlorpromazine